Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia
Romain Aucagne, … , Jean-Noël Bastie, Laurent Delva
Romain Aucagne, … , Jean-Noël Bastie, Laurent Delva
Published May 2, 2011
Citation Information: J Clin Invest. 2011;121(6):2361-2370. https://doi.org/10.1172/JCI45213.
View: Text | PDF
Research Article Hematology Article has an altmetric score of 12

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia

  • Text
  • PDF
Abstract

Transcription intermediary factor 1γ (TIF1γ) was suggested to play a role in erythropoiesis. However, how TIF1γ regulates the development of different blood cell lineages and whether TIF1γ is involved in human hematological malignancies remain to be determined. Here we have shown that TIF1γ was a tumor suppressor in mouse and human chronic myelomonocytic leukemia (CMML). Loss of Tif1g in mouse HSCs favored the expansion of the granulo-monocytic progenitor compartment. Furthermore, Tif1g deletion induced the age-dependent appearance of a cell-autonomous myeloproliferative disorder in mice that recapitulated essential characteristics of human CMML. TIF1γ was almost undetectable in leukemic cells of 35% of CMML patients. This downregulation was related to the hypermethylation of CpG sequences and specific histone modifications in the gene promoter. A demethylating agent restored the normal epigenetic status of the TIF1G promoter in human cells, which correlated with a reestablishment of TIF1γ expression. Together, these results demonstrate that TIF1G is an epigenetically regulated tumor suppressor gene in hematopoietic cells and suggest that changes in TIF1γ expression may be a biomarker of response to demethylating agents in CMML.

Authors

Romain Aucagne, Nathalie Droin, Jérôme Paggetti, Brice Lagrange, Anne Largeot, Arlette Hammann, Amandine Bataille, Laurent Martin, Kai-Ping Yan, Pierre Fenaux, Régine Losson, Eric Solary, Jean-Noël Bastie, Laurent Delva

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Total
Citations: 1 6 2 2 5 6 5 4 5 2 9 4 3 6 4 64
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (64)

Title and authors Publication Year
Low TIF1γ Expression is Associated with Cancer Aggressiveness and Shorter Recurrence-Free Survival in Patients with Esophageal Squamous Cell Carcinoma.
Yamaguchi A, Yokobori T, Sohda M, Watanabe T, Nakazawa N, Sano A, Sakai M, Shiraishi T, Motegi SI, Shirabe K, Saeki H
Annals of surgical oncology 2025
TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha
Romo BA, Karakyriakou B, Cressey L, Brauer BL, Yang H, Warren A, Johnson AL, Kettenbach AN, Miller TW
Cancers 2024
TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors.
McAvera RM, Morgan JJ, Herrero AB, Mills KI, Crawford LJ
Scientific Reports 2024
Anti-TIF1-γ Antibody-Positive Dermatomyositis Leading to Identification of Diffuse Large B-Cell Lymphoma.
Otsuki T, Ishizuka K, Eto H, Nakano H, Kato Y, Sudo H, Motohashi I, Ie K, Ohira Y, Okuse C
Journal of General Internal Medicine 2024
TRIM33 plays a critical role in regulating dendritic cell differentiation and homeostasis by modulating Irf8 and Bcl2l11 transcription.
Shen X, Li X, Wu T, Guo T, Lv J, He Z, Luo M, Zhu X, Tian Y, Lai W, Dong C, Hu X, Wu L
Cellular & molecular immunology 2024
Genome-wide screening identifies Trim33 as an essential regulator of dendritic cell differentiation
Tiniakou I, Hsu PF, Lopez-Zepeda LS, Garipler G, Esteva E, Adams NM, Jang G, Soni C, Lau CM, Liu F, Khodadadi-Jamayran A, Rodrick TC, Jones D, Tsirigos A, Ohler U, Bedford MT, Nimer SD, Kaartinen V, Mazzoni EO, Reizis B
Science Immunology 2024
Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy
McAuley N, Cymer I, McAvera R, Hopkins AM, Glavey SV
European Journal of Haematology 2024
TRIM10 Is Downregulated in Acute Myeloid Leukemia and Plays a Tumor Suppressive Role via Regulating NF-κB Pathway
Li L, Li Q, Zou Z, Huang Z, Chen Y
Cancers 2023
Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions
Zhao HG, Deininger M
Blood 2023
Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling.
Shah K, Kazi JU
Frontiers in Oncology 2022
TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.
Chen M, Lingadahalli S, Narwade N, Lei KMK, Liu S, Zhao Z, Zheng Y, Lu Q, Tang AHN, Poon TCW, Cheung E
EMBO reports 2022
Mouse Models of CMML
E Belotserkovskaya, O Demidov
International journal of molecular sciences 2021
Cell-specific transcriptional control of mitochondrial metabolism by TIF1γ drives erythropoiesis
MP Rossmann, K Hoi, V Chan, BJ Abraham, S Yang, J Mullahoo, M Papanastasiou, Y Wang, I Elia, JR Perlin, EJ Hagedorn, S Hetzel, R Weigert, S Vyas, PP Nag, LB Sullivan, CR Warren, B Dorjsuren, EC Greig, I Adatto, CA Cowan, SL Schreiber, RA Young, A Meissner, MC Haigis, S Hekimi, SA Carr, LI Zon
Science 2021
The TRIM proteins in cancer: from expression to emerging regulatory mechanisms
A Mohammadi, MS Abbasi, S Khorrami, S Khodamoradi, ZM Goldar, F Ebrahimzadeh
Clinical and Translational Oncology 2021
Functional Roles of Bromodomain Proteins in Cancer
SP Boyson, C Gao, K Quinn, J Boyd, H Paculova, S Frietze, KC Glass
Cancers 2021
TRIM33 protects osteoblasts from oxidative stress‐induced apoptosis in osteoporosis by inhibiting FOXO3a ubiquitylation and degradation
D Zou, Z Mou, W Wu, H Liu
Aging Cell 2021
TRIM33 Overexpression Inhibits the Progression of Clear Cell Renal Cell Carcinoma In Vivo and In Vitro
Y Xu, G Wu, J Zhang, J Li, N Ruan, J Zhang, Z Zhang, Y Chen, Q Zhang, Q Xia
BioMed Research International 2020
Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins
JM Rectenwald, SK Guduru, Z Dang, LB Collins, YE Liao, JL Norris-Drouin, SH Cholensky, KW Kaufmann, SM Hammond, DB Kireev, SV Frye, KH Pearce
Molecules (Basel, Switzerland) 2020
A genetic variant controls interferon-β gene expression in human myeloid cells by preventing C/EBP-β binding on a conserved enhancer
A Assouvie, M Rotival, J Hamroune, D Busso, PH Romeo, L Quintana-Murci, G Rousselet, DC Roopenian
PLoS genetics 2020
TIF1 Proteins in Genome Stability and Cancer
RM McAvera, LJ Crawford
Cancers 2020
Analysis of myositis autoantibodies in Chinese patients with cancer‐associated myositis
L Li, C Liu, Q Wang, C Wu, Y Zhang, L Cheng, X Wen, X Zeng, F Zhang, Y Li
Journal of Clinical Laboratory Analysis 2020
The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer
L Yu, X Lin, L Zhang, Q Wu, S Zhang, D Chen, X Pan, Y Huang
International journal of medical sciences 2020
Cellular TRIM33 restrains HIV-1 infection by targeting viral integrase for proteasomal degradation
H Ali, M Mano, L Braga, A Naseem, B Marini, DM Vu, C Collesi, G Meroni, M Lusic, M Giacca
Nature Communications 2019
Trim33 is required for appropriate development of pre-cardiogenic mesoderm
S Rajderkar, JM Mann, C Panaretos, K Yumoto, HD Li, Y Mishina, B Ralston, V Kaartinen
Developmental Biology 2019
Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages
L Bencheikh, MB Diop, J Rivière, A Imanci, G Pierron, S Souquere, A Naimo, M Morabito, M Dussiot, FD Leeuw, C Lobry, E Solary, N Droin
Nature Communications 2019
Prognostic role of Tif1γ expression and circulating tumor cells in patients with breast cancer
F Cai, L Cai, Z Zhou, X Pan, M Wang, S Chen, M Luis, C Cen, E Biskup
Molecular medicine reports 2019
The Roles of TIF1γ in Cancer
C Yu, Z Ding, H Liang, B Zhang, X Chen
Frontiers in Oncology 2019
Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment
Shuang Li, Jing Zhao, Dong Shang, Daniel J Kass, Yutong Zhao
JCI Insight 2018
Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer
L Wang, X Tong, Z Zhou, S Wang, Z Lei, T Zhang, Z Liu, Y Zeng, C Li, J Zhao, Z Su, C Zhang, X Liu, G Xu, HT Zhang
Molecular Cancer 2018
DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features
L Palomo, R Malinverni, M Cabezón, B Xicoy, M Arnan, R Coll, H Pomares, O García, F Fuster-Tormo, J Grau, E Feliu, F Solé, M Buschbeck, L Zamora
Epigenetics : official journal of the DNA Methylation Society 2018
A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset
D Selimoglu-Buet, J Rivière, H Ghamlouch, L Bencheikh, C Lacout, M Morabito, M Diop, G Meurice, M Breckler, A Chauveau, C Debord, F Debeurme, R Itzykson, N Chapuis, C Willekens, O Wagner-Ballon, OA Bernard, N Droin, E Solary
Nature Communications 2018
Turning the tide in myelodysplastic/myeloproliferative neoplasms
MW Deininger, JW Tyner, E Solary
Nature Reviews Cancer 2017
Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer
A Aussy, O Boyer, N Cordel
Frontiers in immunology 2017
Lentivirus-mediated RNA interference of tripartite motif 68 inhibits the proliferation of colorectal cancer cell lines SW1116 and HCT116 in�vitro
Z Tan, X Liu, E Yu, H Wang, L Tang, H Wang, C Fu
Oncology Letters 2017
Macrophage production and activation are dependent on TRIM33
AS Gallouet, F Ferri, V Petit, A Parcelier, D Lewandowski, N Gault, V Barroca, SL Gras, E Soler, F Grosveld, I Davidson, PH Romeo
Oncotarget 2017
TRIM proteins in blood cancers
LJ Crawford, CK Johnston, AE Irvine
Journal of Cell Communication and Signaling 2017
Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms
X Shi, VT Mihaylova, L Kuruvilla, F Chen, S Viviano, M Baldassarre, D Sperandio, R Martinez, P Yue, JG Bates, DG Breckenridge, J Schlessinger, BE Turk, DA Calderwood
Proceedings of the National Academy of Sciences 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
J Merlevede, N Droin, T Qin, K Meldi, K Yoshida, M Morabito, E Chautard, D Auboeuf, P Fenaux, T Braun, R Itzykson, S Botton, B Quesnel, T Commes, E Jourdan, W Vainchenker, O Bernard, N Pata-Merci, S Solier, V Gayevskiy, ME Dinger, MJ Cowley, D Selimoglu-Buet, V Meyer, F Artiguenave, JF Deleuze, C Preudhomme, MR Stratton, LB Alexandrov, E Padron, S Ogawa, S Koscielny, M Figueroa, E Solary
Nature Communications 2016
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy
M Satoh, S Tanaka, A Ceribelli, SJ Calise, EK Chan
Clinical Reviews in Allergy & Immunology 2015
Chronic myelomonocytic leukemia: Forefront of the field in 2015
CB Benton, A Nazha, N Pemmaraju, G Garcia-Manero
Critical Reviews in Oncology/Hematology 2015
Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial–mesenchymal transition in non-small-cell lung cancer
L Wang, H Yang, Z Lei, J Zhao, Y Chen, P Chen, C Li, Y Zeng, Z Liu, X Liu, HT Zhang
Oncogene 2015
Tumour suppressor TRIM33 targets nuclear β-catenin degradation
J Xue, Y Chen, Y Wu, Z Wang, A Zhou, S Zhang, K Lin, K Aldape, S Majumder, Z Lu, S Huang
Nature Communications 2015
The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer: ( A ) Negative selection shRNA screen targeting chromatin regulators in murine B cell acute lymphoblastic leukemia (B-ALL). shRNAs are rank ordered by the fold-change in GFP positivity over 10 days in culture, which represents a competition-based assay in which loss of GFP positivity reflects shRNA-postive cells becoming outcompeted by shRNA-negative cells. ( B – E ) Competition-based assays and Western blotting to evaluate the effect of TRIM33 shRNAs on B-ALL, 38B9, acute myeloid leukemia (AML), or T-cell acute lymphoblastic leukemia (T-ALL) cells. GFP percentages are normalized to day 2 measurements. Results are the average of three biological replicates. ( F ) Annexin V/DAPI staining following transduction of B-ALL cells with the indicated MLS shRNAs on day 3 post-transduction. Representative experiment of three biological replicates is shown. ( G ) shRNA transgenic mouse strategy. TRE: tet(doxycycline) response element; rtTA-M2: reverse tet transactivator M2 variant (tet-on). ( H ) Western blotting performed of indicated tissue lysates prepared from mice treated with dox for 4 weeks. Representative experiment of three biological replicates is shown. ( I – J ) Flow cytometry analysis using the indicated antibody stainings of whole bone marrow or spleen. B220 and Cd19: B lymphoid, Ter119: erythroid, Gr1 and Mac1: myeloid, Cd3: T lymphoid. Gating was performed on GFP + /shRNA + cells prior to quantifying marker positivity. The GFP + percentage in bone marrow was ∼75% and in the spleen was ∼15%. Mice were administered dox for 1 week or 4 weeks, with both timepoints giving similar results. Results shown are the average 4 or 5 mice. All error bars in this figure represent S.E.M
E Wang, S Kawaoka, JS Roe, J Shi, AF Hohmann, Y Xu, AS Bhagwat, Y Suzuki, JB Kinney, CR Vakoc
eLife 2015
TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients
L Kassem, M Deygas, L Fattet, J Lopez, T Goulvent, E Lavergne, S Chabaud, N Carrabin, N Chopin, T Bachelot, G Gillet, I Treilleux, R Rimokh
BMC Cancer 2015
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia
D Selimoglu-Buet, O Wagner-Ballon, V Saada, V Bardet, R Itzykson, L Bencheikh, M Morabito, E Met, C Debord, E Benayoun, AM Nloga, P Fenaux, T Braun, C Willekens, B Quesnel, L Ades, M Fontenay, P Rameau, N Droin, S Koscielny, E Solary
Blood 2015
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development
AL Joly, A Deepti, A Seignez, A Goloudina, S Hebrard, E Schmitt, S Richaud, E Fourmaux, A Hammann, A Collura, M Svrcek, G Jego, E Robinet, E Solary, O Demidov, E Kohli, C Garrido
Oncogene 2015
TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome
Y Chen, Y Guo, H Yang, G Shi, G Xu, Y Na, J Shi, D Chen
Oncotarget 2015
Tif1  regulates the TGF- 1 receptor and promotes physiological aging of hematopoietic stem cells
R Quere, L Saint-Paul, V Carmignac, RZ Martin, ML Chretien, A Largeot, A Hammann, JP de Barros, JN Bastie, L Delva
Proceedings of the National Academy of Sciences 2014
Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice
D Selimoglu-Buet, E Solary
Current Hematologic Malignancy Reports 2014
Expression of the Dermatomyositis Autoantigen Transcription Intermediary Factor 1γ in Regenerating Muscle: TIF1γ Expression in Regenerating Muscle
P Mohassel, P Rosen, L Casciola-Rosen, K Pak, AL Mammen
Arthritis & Rheumatology 2014
The E3 Ubiquitin Ligase Tripartite Motif 33 Is Essential for Cytosolic RNA-Induced NLRP3 Inflammasome Activation
L Weng, H Mitoma, C Tricot, M Bao, Y Liu, Z Zhang, YJ Liu
Journal of immunology (Baltimore, Md. : 1950) 2014
TiF1-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes
X Bai, JJ Trowbridge, E Riley, JA Lee, A DiBiase, VM Kaartinen, SH Orkin, LI Zon
Developmental Biology 2013
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases
E Solary, OA Bernard, A Tefferi, F Fuks, W Vainchenker
Leukemia 2013
Tripartite Motif-containing 33 (TRIM33) Protein Functions in the Poly(ADP-ribose) Polymerase (PARP)-dependent DNA Damage Response through Interaction with Amplified in Liver Cancer 1 (ALC1) Protein
A Kulkarni, J Oza, M Yao, H Sohail, V Ginjala, A Tomas-Loba, Z Horejsi, AR Tan, SJ Boulton, S Ganesan
The Journal of biological chemistry 2013
Dynamic Regulation of Tgf-B Signaling by Tif1γ: A Computational Approach
G Andrieux, L Fattet, ML Borgne, R Rimokh, N Théret
PloS one 2012
Myeloid malignancies: mutations, models and management
A Murati, M Brecqueville, R Devillier, MJ Mozziconacci, V Gelsi-Boyer, D Birnbaum
BMC Cancer 2012
Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations
JN Bastie, R Aucagne, N Droin, E Solary, L Delva
Cellular and Molecular Life Sciences 2012
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts
V Gelsi-Boyer, N Cervera, F Bertucci, M Brecqueville, P Finetti, A Murati, C Arnoulet, MJ Mozziconacci, KI Mills, NC Cross, N Vey, D Birnbaum
Haematologica 2012
Regulation of TGF-β signal transduction by mono- and deubiquitylation of Smads
S Dupont, M Inui, SJ Newfeld
FEBS Letters 2012
Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis
M Satoh, JY Chan, SJ Ross, Y Li, Y Yamasaki, H Yamada, MV Mercado, MH Petri, LJ Jara, MA Saavedra, C Cruz-Reyes, ES Sobel, WH Reeves, A Ceribelli, EK Chan
Arthritis Research & Therapy 2012
Common Pathways of Autoimmune Inflammatory Myopathies and Genetic Neuromuscular Disorders
M Satoh, A Ceribelli, EK Chan
Clinical Reviews in Allergy & Immunology 2011
The TIF1α-related TRIM cofactors couple chromatin modifications to transcriptional regulation, signaling and tumor suppression
B Herquel, K Ouararhni, I Davidson
Transcription 2011
TRIM proteins and cancer
S Hatakeyama
Nature Reviews Cancer 2011
Adenovirus E4orf3 Targets Transcriptional Intermediary Factor 1  for Proteasome-Dependent Degradation during Infection
NA Forrester, RN Patel, T Speiseder, P Groitl, GG Sedgwick, NJ Shimwell, RI Seed, PO Catnaigh, CJ McCabe, GS Stewart, T Dobner, RJ Grand, A Martin, AS Turnell
Journal of virology 2011

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 4 patents
Referenced in 1 Wikipedia pages
68 readers on Mendeley
1 readers on CiteULike
See more details